Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.
about
EGF receptor signaling, phosphorylation, ubiquitylation and endocytosis in tumors in vivo.One-pot three-component synthesis of novel spirooxindoles with potential cytotoxic activity against triple-negative breast cancer MDA-MB-231 cells.Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinomas: A Single Center Study from IranHow shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.Immunotherapeutic interventions of Triple Negative Breast Cancer.
P2860
Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-EGFR monoclonal antibodie ...... triple-negative breast cancer.
@en
Anti-EGFR monoclonal antibodie ...... triple-negative breast cancer.
@nl
type
label
Anti-EGFR monoclonal antibodie ...... triple-negative breast cancer.
@en
Anti-EGFR monoclonal antibodie ...... triple-negative breast cancer.
@nl
prefLabel
Anti-EGFR monoclonal antibodie ...... triple-negative breast cancer.
@en
Anti-EGFR monoclonal antibodie ...... triple-negative breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Anti-EGFR monoclonal antibodie ...... triple-negative breast cancer
@en
P2093
Abderrahim El Guerrab
Fabrice Kwiatkowski
Frédérique Penault-Llorca
Yves-Jean Bignon
P2860
P304
73618-73637
P356
10.18632/ONCOTARGET.12037
P407
P577
2016-11-01T00:00:00Z